Bioterrorism: A Billion-Plus for Countermeasures, But Also New Strings
This article was originally published in Start Up
Executive SummaryThe new US bioterrorism bill will direct hundreds of millions of dollars toward bolstering the US pharmaceutical stockpile. At the same time, it imposes reporting and other obligations on companies. On the other hand, some regulatory burdens on companies will be eased. And because FDA may now find now in an unusual dual position with respect to risk taking--promoting industry while at the same time regulating--it could create a different dynamic with companies.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.